BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 35045875)

  • 21. The Next Generation of JAK Inhibitors: an Update on Fedratinib, Momelotonib, and Pacritinib.
    Patel AA; Odenike O
    Curr Hematol Malig Rep; 2020 Dec; 15(6):409-418. PubMed ID: 32780250
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.
    Verstovsek S; Gerds AT; Vannucchi AM; Al-Ali HK; Lavie D; Kuykendall AT; Grosicki S; Iurlo A; Goh YT; Lazaroiu MC; Egyed M; Fox ML; McLornan D; Perkins A; Yoon SS; Gupta V; Kiladjian JJ; Granacher N; Lee SE; Ocroteala L; Passamonti F; Harrison CN; Klencke BJ; Ro S; Donahue R; Kawashima J; Mesa R;
    Lancet; 2023 Jan; 401(10373):269-280. PubMed ID: 36709073
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial.
    Gupta V; Oh S; Devos T; Dubruille V; Catalano J; Somervaille TCP; Platzbecker U; Giraldo P; Kosugi H; Sacha T; Mayer J; Illes A; Ellis C; Wang Z; Gonzalez Carreras FJ; Strouse B; Mesa R
    Leuk Lymphoma; 2024 Mar; ():1-13. PubMed ID: 38501751
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Managing side effects of JAK inhibitors for myelofibrosis in clinical practice.
    Saeed I; McLornan D; Harrison CN
    Expert Rev Hematol; 2017 Jul; 10(7):617-625. PubMed ID: 28571503
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Momelotinib expands the therapeutic armamentarium for myelofibrosis: Impact on hierarchy of treatment choices.
    Tefferi A; Pardanani A; Gangat N
    Am J Hematol; 2024 Feb; 99(2):300-308. PubMed ID: 38164985
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SOHO State of the Art Updates and Next Questions: Novel Therapies in Development for Myelofibrosis.
    Chifotides HT; Bose P; Masarova L; Pemmaraju N; Verstovsek S
    Clin Lymphoma Myeloma Leuk; 2022 Apr; 22(4):210-223. PubMed ID: 34840087
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium.
    Griesshammer M; Sadjadian P
    Expert Opin Pharmacother; 2017 Dec; 18(18):1929-1938. PubMed ID: 29134817
    [TBL] [Abstract][Full Text] [Related]  

  • 28. How many JAK inhibitors in myelofibrosis?
    Ferreira BV; Harrison C
    Best Pract Res Clin Haematol; 2014 Jun; 27(2):187-95. PubMed ID: 25189729
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Myelofibrosis: an update on drug therapy in 2016.
    Bose P; Verstovsek S
    Expert Opin Pharmacother; 2016 Dec; 17(18):2375-2389. PubMed ID: 27774820
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis.
    Oh ST; Mesa RA; Harrison CN; Bose P; Gerds AT; Gupta V; Scott BL; Kiladjian JJ; Lucchesi A; Kong T; Buckley SA; Tyavanagimatt S; Harder BG; Roman-Torres K; Smith J; Craig AR; Mascarenhas J; Verstovsek S
    Blood Adv; 2023 Oct; 7(19):5835-5842. PubMed ID: 37552106
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis.
    Pardanani A; Gotlib J; Roberts AW; Wadleigh M; Sirhan S; Kawashima J; Maltzman JA; Shao L; Gupta V; Tefferi A
    Leukemia; 2018 Apr; 32(4):1035-1038. PubMed ID: 29263442
    [No Abstract]   [Full Text] [Related]  

  • 32. Anemia in myelofibrosis: Current and emerging treatment options.
    Passamonti F; Harrison CN; Mesa RA; Kiladjian JJ; Vannucchi AM; Verstovsek S
    Crit Rev Oncol Hematol; 2022 Dec; 180():103862. PubMed ID: 36332787
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis.
    Oh ST; Verstovsek S; Gupta V; Platzbecker U; Devos T; Kiladjian JJ; McLornan DP; Perkins A; Fox ML; McMullin MF; Mead AJ; Egyed M; Mayer J; Sacha T; Kawashima J; Huang M; Strouse B; Mesa R
    EJHaem; 2024 Feb; 5(1):105-116. PubMed ID: 38406514
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictors of anemia response to momelotinib therapy in myelofibrosis and impact on survival.
    Gangat N; Begna KH; Al-Kali A; Hogan W; Litzow M; Pardanani A; Tefferi A
    Am J Hematol; 2023 Feb; 98(2):282-289. PubMed ID: 36349465
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Meaningful Symptomatic Change in Patients With Myelofibrosis From the SIMPLIFY Studies.
    Hudgens S; Verstovsek S; Floden L; Harrison CN; Palmer J; Gupta V; McLornan D; McMullin MF; Kiladjian JJ; Foltz L; Platzbecker U; Fox ML; Mead AJ; Ross DM; Oh ST; Perkins AA; Leahy MF; Deheshi S; Donahue R; Klencke BJ; Mesa RA
    Value Health; 2024 May; 27(5):607-613. PubMed ID: 38311180
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety considerations when treating myelofibrosis.
    O'Sullivan JM; McLornan DP; Harrison CN
    Expert Opin Drug Saf; 2016 Sep; 15(9):1185-92. PubMed ID: 27187785
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis.
    Gupta V; Mesa RA; Deininger MW; Rivera CE; Sirhan S; Brachmann CB; Collins H; Kawashima J; Xin Y; Verstovsek S
    Haematologica; 2017 Jan; 102(1):94-102. PubMed ID: 27634203
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Momelotinib treatment-emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis.
    Abdelrahman RA; Begna KH; Al-Kali A; Hogan WJ; Litzow MR; Pardanani A; Tefferi A
    Br J Haematol; 2015 Apr; 169(1):77-80. PubMed ID: 25511866
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SOHO State of the Art Updates and Next Questions: Identifying and Treating "Progression" in Myelofibrosis.
    Bose P; Verstovsek S
    Clin Lymphoma Myeloma Leuk; 2021 Oct; 21(10):641-649. PubMed ID: 34272171
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of myelofibrosis after ruxolitinib failure.
    Bose P; Verstovsek S
    Leuk Lymphoma; 2020 Aug; 61(8):1797-1809. PubMed ID: 32297800
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.